SG/CALL/EVOTEC/14/1/20.06.25 Share Price

Warrant

DE000SU74V42

Market Closed - Boerse Frankfurt Warrants 20:50:22 28/06/2024 BST
0.91 EUR +12.35% Intraday chart for SG/CALL/EVOTEC/14/1/20.06.25
Current month+44.44%
1 month+15.19%
Date Price Change
28/06/24 0.91 +12.35%
27/06/24 0.81 -10.99%
26/06/24 0.91 +13.75%
25/06/24 0.8 +14.29%
24/06/24 0.7 +4.48%

Real-time Boerse Frankfurt Warrants

Last update June 28, 2024 at 08:50 pm

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying EVOTEC SE
IssuerLogo Issuer Société Générale Société Générale
WKN SU74V4
ISINDE000SU74V42
Date issued 09/02/2024
Strike 14
Maturity 20/06/2025 (355 Days)
Parity 1 : 1
Emission price 4.03
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 4.04
Lowest since issue 0.43
Delta0.36x
Omega 3.259
Premium66.96x
Gearing9.11x
Moneyness 0.6411
Difference Strike 5.025
Difference Strike %+35.89%
Spread 0.15
Spread %14.15%
Theoretical value 0.9850
Implied Volatility 61.77 %
Total Loss Probability 83.54 %
Intrinsic value 0.000000
Present value 0.9850
Break even 14.99 €
Theta-0.02x
Vega0.03x
Rho0.02x

Company Profile

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Sector
-
More about the company

Ratings for Evotec SE

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Evotec SE

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
8.975 EUR
Average target price
20.79 EUR
Spread / Average Target
+131.64%
Consensus